Close Menu

Exelixis

Originally published March 25.
The European Commission has approved Cometriq (cabozantinib) as a treatment for medullary thyroid cancer (MTC) patients.

Originally published Dec. 23.
EU's CHMP Issues Positive Opinion Exelixis' Cometriq for Medullary Thyroid Cancer

A team led by investigators at Cedars-Sinai Medical Center and the University of California, Los Angeles has developed a new approach for analyzing circulating tumor cells obtained from prostate cancer patients using chip- and sequencing-based applications.

European Commission Approves Vertex's Personalized CF Drug Kalydeco

Gaithersburg West Master Plan, Ben Franklin Technology Partners, University of Houston Institute of Biomedical Research, Connecticut Economic Development Consolidations, South San Francisco Life Sciences Career Fair, New York City Biotechnology Tax Credit

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.